#begin document (wsj_1904.en); part 000
wsj_1904.en	0	0	Britain	NNP	*	_	_	6	_	(4
wsj_1904.en	0	1	's	POS	*	_	_	1	_	-
wsj_1904.en	0	2	Monopolies	NNP	*	_	_	4	_	-
wsj_1904.en	0	3	and	CC	*	_	_	6	_	-
wsj_1904.en	0	4	Mergers	NNP	*	_	_	4	_	-
wsj_1904.en	0	5	Commission	NNP	*	_	_	8	_	4)
wsj_1904.en	0	6	Wednesday	NNP	*	_	_	8	_	-
wsj_1904.en	0	7	cleared	VBD	*	_	_	0	_	-
wsj_1904.en	0	8	Rhone-Poulenc	NNP	*	_	_	10	_	(1|(2
wsj_1904.en	0	9	S.A.	NNP	*	_	_	12	_	-
wsj_1904.en	0	10	's	POS	*	_	_	10	_	1)
wsj_1904.en	0	11	purchase	NN	*	_	_	8	_	-
wsj_1904.en	0	12	of	IN	*	_	_	12	_	-
wsj_1904.en	0	13	a	DT	*	_	_	17	_	-
wsj_1904.en	0	14	specialty	NN	*	_	_	17	_	-
wsj_1904.en	0	15	bulk-chemical	NN	*	_	_	17	_	-
wsj_1904.en	0	16	unit	NN	*	_	_	13	_	-
wsj_1904.en	0	17	from	IN	*	_	_	12	_	-
wsj_1904.en	0	18	Monsanto	NNP	*	_	_	20	_	(3
wsj_1904.en	0	19	Co.	NNP	*	_	_	18	_	2)|3)
wsj_1904.en	0	20	,	,	*	_	_	8	_	-
wsj_1904.en	0	21	saying	VBG	*	_	_	8	_	-
wsj_1904.en	0	22	the	DT	*	_	_	24	_	(2
wsj_1904.en	0	23	purchase	NN	*	_	_	25	_	2)
wsj_1904.en	0	24	was	VBD	*	_	_	22	_	-
wsj_1904.en	0	25	unlikely	JJ	*	_	_	25	_	-
wsj_1904.en	0	26	to	TO	*	_	_	26	_	-
wsj_1904.en	0	27	have	VB	*	_	_	27	_	-
wsj_1904.en	0	28	any	DT	*	_	_	31	_	-
wsj_1904.en	0	29	lasting	JJ	*	_	_	31	_	-
wsj_1904.en	0	30	impact	NN	*	_	_	28	_	-
wsj_1904.en	0	31	on	IN	*	_	_	31	_	-
wsj_1904.en	0	32	U.K.	NNP	*	_	_	35	_	-
wsj_1904.en	0	33	industrial	JJ	*	_	_	35	_	-
wsj_1904.en	0	34	consumers	NNS	*	_	_	32	_	-
wsj_1904.en	0	35	.	.	*	_	_	8	_	-

wsj_1904.en	0	0	The	DT	*	_	_	38	_	(4
wsj_1904.en	0	1	commission	NN	*	_	_	60	_	4)
wsj_1904.en	0	2	,	,	*	_	_	38	_	-
wsj_1904.en	0	3	which	WDT	*	_	_	42	_	(4)
wsj_1904.en	0	4	was	VBD	*	_	_	42	_	-
wsj_1904.en	0	5	asked	VBN	*	_	_	38	_	-
wsj_1904.en	0	6	to	TO	*	_	_	42	_	-
wsj_1904.en	0	7	study	VB	*	_	_	43	_	-
wsj_1904.en	0	8	the	DT	*	_	_	46	_	(2
wsj_1904.en	0	9	deal	NN	*	_	_	44	_	2)
wsj_1904.en	0	10	by	IN	*	_	_	42	_	-
wsj_1904.en	0	11	the	DT	*	_	_	49	_	-
wsj_1904.en	0	12	Department	NNP	*	_	_	47	_	-
wsj_1904.en	0	13	of	IN	*	_	_	49	_	-
wsj_1904.en	0	14	Trade	NNP	*	_	_	52	_	-
wsj_1904.en	0	15	and	CC	*	_	_	50	_	-
wsj_1904.en	0	16	Industry	NNP	*	_	_	52	_	-
wsj_1904.en	0	17	after	IN	*	_	_	42	_	-
wsj_1904.en	0	18	its	PRP$	*	_	_	56	_	(2)
wsj_1904.en	0	19	announcement	NN	*	_	_	54	_	-
wsj_1904.en	0	20	in	IN	*	_	_	56	_	-
wsj_1904.en	0	21	February	NNP	*	_	_	57	_	-
wsj_1904.en	0	22	,	,	*	_	_	38	_	-
wsj_1904.en	0	23	said	VBD	*	_	_	0	_	-
wsj_1904.en	0	24	the	DT	*	_	_	62	_	(5
wsj_1904.en	0	25	diversity	NN	*	_	_	73	_	-
wsj_1904.en	0	26	of	IN	*	_	_	62	_	-
wsj_1904.en	0	27	global	JJ	*	_	_	65	_	-
wsj_1904.en	0	28	supply	NN	*	_	_	63	_	-
wsj_1904.en	0	29	of	IN	*	_	_	65	_	-
wsj_1904.en	0	30	chemicals	NNS	*	_	_	66	_	(6)
wsj_1904.en	0	31	used	VBN	*	_	_	67	_	-
wsj_1904.en	0	32	in	IN	*	_	_	68	_	-
wsj_1904.en	0	33	making	VBG	*	_	_	69	_	-
wsj_1904.en	0	34	analgesic	JJ	*	_	_	72	_	-
wsj_1904.en	0	35	drugs	NNS	*	_	_	70	_	5)
wsj_1904.en	0	36	was	VBD	*	_	_	60	_	-
wsj_1904.en	0	37	great	JJ	*	_	_	75	_	-
wsj_1904.en	0	38	enough	RB	*	_	_	73	_	-
wsj_1904.en	0	39	to	TO	*	_	_	75	_	-
wsj_1904.en	0	40	offset	VB	*	_	_	76	_	-
wsj_1904.en	0	41	the	DT	*	_	_	82	_	(7
wsj_1904.en	0	42	dominant	JJ	*	_	_	82	_	-
wsj_1904.en	0	43	U.K.	NNP	*	_	_	82	_	-
wsj_1904.en	0	44	market	NN	*	_	_	82	_	-
wsj_1904.en	0	45	share	NN	*	_	_	77	_	7)
wsj_1904.en	0	46	Rhone-Poulenc	NNP	*	_	_	84	_	(1)
wsj_1904.en	0	47	would	MD	*	_	_	82	_	-
wsj_1904.en	0	48	gain	VB	*	_	_	84	_	-
wsj_1904.en	0	49	through	IN	*	_	_	85	_	-
wsj_1904.en	0	50	the	DT	*	_	_	88	_	(2
wsj_1904.en	0	51	acquisition	NN	*	_	_	86	_	2)
wsj_1904.en	0	52	.	.	*	_	_	60	_	-

wsj_1904.en	0	0	The	DT	*	_	_	93	_	(1
wsj_1904.en	0	1	French	NNP	*	_	_	93	_	-
wsj_1904.en	0	2	chemical	NN	*	_	_	93	_	-
wsj_1904.en	0	3	giant	NN	*	_	_	94	_	1)
wsj_1904.en	0	4	would	MD	*	_	_	0	_	-
wsj_1904.en	0	5	hold	VB	*	_	_	94	_	-
wsj_1904.en	0	6	an	DT	*	_	_	99	_	-
wsj_1904.en	0	7	80	CD	*	_	_	99	_	-
wsj_1904.en	0	8	%	NN	*	_	_	97	_	-
wsj_1904.en	0	9	share	NN	*	_	_	95	_	-
wsj_1904.en	0	10	of	IN	*	_	_	99	_	-
wsj_1904.en	0	11	the	DT	*	_	_	103	_	-
wsj_1904.en	0	12	U.K.	NNP	*	_	_	103	_	-
wsj_1904.en	0	13	market	NN	*	_	_	100	_	-
wsj_1904.en	0	14	for	IN	*	_	_	103	_	-
wsj_1904.en	0	15	salicylic	JJ	*	_	_	106	_	-
wsj_1904.en	0	16	acid	NN	*	_	_	110	_	-
wsj_1904.en	0	17	,	,	*	_	_	110	_	-
wsj_1904.en	0	18	methyl	NN	*	_	_	109	_	-
wsj_1904.en	0	19	salicylate	NN	*	_	_	110	_	-
wsj_1904.en	0	20	and	CC	*	_	_	104	_	-
wsj_1904.en	0	21	bulk	JJ	*	_	_	112	_	-
wsj_1904.en	0	22	aspirin	NN	*	_	_	110	_	-
wsj_1904.en	0	23	.	.	*	_	_	94	_	-

wsj_1904.en	0	0	The	DT	*	_	_	115	_	(4
wsj_1904.en	0	1	commission	NN	*	_	_	116	_	4)
wsj_1904.en	0	2	found	VBD	*	_	_	0	_	-
wsj_1904.en	0	3	that	IN	*	_	_	116	_	-
wsj_1904.en	0	4	if	IN	*	_	_	129	_	-
wsj_1904.en	0	5	the	DT	*	_	_	121	_	(9|(11
wsj_1904.en	0	6	British	JJ	*	_	_	121	_	-
wsj_1904.en	0	7	government	NN	*	_	_	122	_	9)
wsj_1904.en	0	8	attempted	VBD	*	_	_	118	_	-
wsj_1904.en	0	9	to	TO	*	_	_	122	_	-
wsj_1904.en	0	10	block	VB	*	_	_	123	_	-
wsj_1904.en	0	11	the	DT	*	_	_	126	_	(2
wsj_1904.en	0	12	merger	NN	*	_	_	124	_	2)|11)
wsj_1904.en	0	13	,	,	*	_	_	129	_	-
wsj_1904.en	0	14	Rhone-Poulenc	NNP	*	_	_	129	_	(1)
wsj_1904.en	0	15	would	MD	*	_	_	117	_	-
wsj_1904.en	0	16	likely	RB	*	_	_	131	_	-
wsj_1904.en	0	17	respond	VB	*	_	_	129	_	-
wsj_1904.en	0	18	by	IN	*	_	_	131	_	-
wsj_1904.en	0	19	closing	VBG	*	_	_	132	_	-
wsj_1904.en	0	20	the	DT	*	_	_	136	_	(10
wsj_1904.en	0	21	salicylates	NNS	*	_	_	136	_	-
wsj_1904.en	0	22	plant	NN	*	_	_	133	_	10)
wsj_1904.en	0	23	Monsanto	NNP	*	_	_	138	_	(3)
wsj_1904.en	0	24	operates	VBZ	*	_	_	136	_	-
wsj_1904.en	0	25	in	IN	*	_	_	136	_	-
wsj_1904.en	0	26	Wales	NNP	*	_	_	139	_	-
wsj_1904.en	0	27	,	,	*	_	_	131	_	-
wsj_1904.en	0	28	removing	VBG	*	_	_	131	_	-
wsj_1904.en	0	29	the	DT	*	_	_	144	_	-
wsj_1904.en	0	30	matter	NN	*	_	_	142	_	-
wsj_1904.en	0	31	from	IN	*	_	_	142	_	-
wsj_1904.en	0	32	U.K.	NNP	*	_	_	147	_	-
wsj_1904.en	0	33	jurisdiction	NN	*	_	_	145	_	-
wsj_1904.en	0	34	.	.	*	_	_	116	_	-

#end document 